Wells Fargo & Company MN Acquires 16,853 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Wells Fargo & Company MN raised its holdings in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 30.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 71,720 shares of the company’s stock after buying an additional 16,853 shares during the period. Wells Fargo & Company MN’s holdings in Atossa Therapeutics were worth $68,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Gallagher Capital Advisors LLC bought a new stake in shares of Atossa Therapeutics in the 4th quarter worth $25,000. Intech Investment Management LLC grew its stake in shares of Atossa Therapeutics by 224.0% in the 4th quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock worth $59,000 after acquiring an additional 43,449 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Atossa Therapeutics by 148.2% in the 4th quarter. SG Americas Securities LLC now owns 103,865 shares of the company’s stock worth $98,000 after acquiring an additional 62,016 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Atossa Therapeutics by 177.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock worth $227,000 after acquiring an additional 95,643 shares in the last quarter. Finally, Barclays PLC grew its position in Atossa Therapeutics by 280.9% during the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after buying an additional 123,683 shares during the period. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Stock Up 6.3%

NASDAQ ATOS opened at $0.89 on Wednesday. The company has a market cap of $114.96 million, a PE ratio of -4.05 and a beta of 1.01. Atossa Therapeutics, Inc. has a 52 week low of $0.55 and a 52 week high of $1.71. The firm’s 50-day simple moving average is $0.72 and its two-hundred day simple moving average is $0.93.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, equities research analysts anticipate that Atossa Therapeutics, Inc. will post -0.22 EPS for the current year.

Wall Street Analysts Forecast Growth

ATOS has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday, March 26th. Ascendiant Capital Markets increased their price target on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the company a “buy” rating in a research report on Monday, April 21st.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.